Pain, IntractableNCT06537375
Use of Ketamine in Severe Pain Syndromes
An observational study of Pain, Intractable and Pain, Chronic, run by Erasme University Hospital at 1 site in Belgium.
Trial summary
Ketamine has been shown to have a certain efficiency in chronic pain syndromes. However, it is still not clearly known what is its efficiency and how ketamine is used in real world patients. In this retrospective study, all patients treated with ketamine for chronic pain in our hospital will be reviewed. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Pain, Intractable, Pain, Chronic, Pain Syndrome
- How many people
- 89 participants
- Where
- 1 siteBelgium
- Study dates
- 1 Aug 2024to 20 Feb 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: All patients who received ketamine as treatment for a pain syndrome during january 2010 until june 2024 at Erasme University Hospital
Who may be able to join
- All patients who received ketamine as treatment for a pain syndrome during january 2010 until june 2024 at Erasme University Hospital
Who cannot join
- Age < 18 years
- Patients who expressed their opposition to the use of their medical data
- incomplete medical chart
Trial locations and contacts
1 site in 1 country.
Belgium1 site
Hôpital Universitaire de Bruxelles - Hôpital erasme
Brussels, 1070
About this study
Official title: Use of Intravenous Ketamine in Patients with Severe Chronic Pain Syndromes
Ketamine has been shown to have a certain efficiency in chronic pain syndromes. However, it is still not clearly known what is its efficiency and how ketamine is used in real world patients. In this retrospective study, all patients treated with ketamine for chronic pain in our hospital will be reviewed. Patients demographics, pain syndromes as well as outcome criteria will be collected to describe the use of ketamine in pain syndromes.
Read the detailed description
The American Society of Regional Anesthesia and Pain Medicine, together with the American Academy of Pain and the American Society of Anesthesiologists published a consensus guideline in 2018 on the use of ketamine in chronic pain. A review of medical charts of all patients who received ketamine for chronic pain between january 2010 and june 2024 will be done. Demographic data, detailed pain scores, as well as description of the type of pain will be collected. Ketamine usage will be recorded for the dosage, as well as duration of the treatment. Outcome will be measured by before/after pain scores for neuropathic pain, as well as on a visual analog scale. A more global score (good-medium-no effect) will also be collected to get the patient's impression on their treatment. Concomitant pain medication will be collected.
- Conditions
- Pain, Intractable, Pain, Chronic, Pain Syndrome, Pain Measurement
- Medical subject headings
- Pain, Intractable, Chronic Pain, Somatoform Disorders
What is being measured
The primary outcome is the main question the study is designed to answer.
Patient satisfaction
A scale (good-medium-no effect) of the efficacity of ketamine on their pain syndrome
Measured: 6 month
DN4
Neuropathic pain scale 4
Measured: 6 month
VAS
Visual analog scale of the pain intensity
Measured: 6 month
Secondary outcomes (1)
Concomitant pain medications
Number of concomitant pain medications used by the patient
Measured: 6 month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Aug 2024
- Study start1 Aug 2024
- Primary completion20 Feb 2025
- Study completion20 Feb 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pain, IntractableStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 89 participants (actual)
Sponsor and investigators
- Lead sponsor
- Erasme University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06537375
- Sponsor's protocol ID
- SRB2024171
- Status last verified
- Aug 2024
- First submitted
- 1 Aug 2024
- Last updated
- 25 Feb 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 25 Feb 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Use of Intravenous Ketamine in Patients with Severe Chronic Pain Syndromes
- ClinicalTrials.gov ID
- NCT06537375
- Acronym / sponsor ID
- SRB2024171
- Conditions
- Pain, Intractable, Pain, Chronic, Pain Syndrome, Pain Measurement
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 89 participants (actual)
- Lead sponsor
- Erasme University HospitalUniversity, hospital or other
- Study start
- 1 Aug 2024 (actual)
- Primary completion
- 20 Feb 2025 (actual)
- Study completion
- 20 Feb 2025 (actual)
- First posted
- 5 Aug 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Ketamine has been shown to have a certain efficiency in chronic pain syndromes. However, it is still not clearly known what is its efficiency and how ketamine is used in real world patients. In this retrospective study, all patients treated with ketamine for chronic pain in our hospital will be reviewed. Patients demographics, pain syndromes as well as outcome criteria will be collected to describe the use of ketamine in pain syndromes.
Detailed description
The American Society of Regional Anesthesia and Pain Medicine, together with the American Academy of Pain and the American Society of Anesthesiologists published a consensus guideline in 2018 on the use of ketamine in chronic pain. A review of medical charts of all patients who received ketamine for chronic pain between january 2010 and june 2024 will be done. Demographic data, detailed pain scores, as well as description of the type of pain will be collected. Ketamine usage will be recorded for the dosage, as well as duration of the treatment. Outcome will be measured by before/after pain scores for neuropathic pain, as well as on a visual analog scale. A more global score (good-medium-no effect) will also be collected to get the patient's impression on their treatment. Concomitant pain medication will be collected.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- All patients who received ketamine as treatment for a pain syndrome during january 2010 until june 2024 at Erasme University Hospital
Key inclusion criteria (1 listed)
- All patients who received ketamine as treatment for a pain syndrome during january 2010 until june 2024 at Erasme University Hospital
Key exclusion criteria (3 listed)
- Age < 18 years
- Patients who expressed their opposition to the use of their medical data
- incomplete medical chart
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Patient satisfaction
Time frame: 6 month
A scale (good-medium-no effect) of the efficacity of ketamine on their pain syndrome
DN4
Time frame: 6 month
Neuropathic pain scale 4
VAS
Time frame: 6 month
Visual analog scale of the pain intensity
1 secondary outcome
Concomitant pain medications
Time frame: 6 month
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Feb 2025.
Related trials for Pain, Intractable
RecruitingObservational study
Post Market Evaluation of Real World Outcomes and Durability to Support Implantable Inceptiv™ Spinal Cord Stimulation Therapy
Chronic Pain, Intractable Pain
Not yet recruitingPhase 1/2
Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone Pain
Intractable Pain, Palliative Care
Recruiting
Managing Pain Using Optimized Sequences by Adjusting Parameters With Independent Current Control
Chronic Pain, Intractable Pain
Not yet recruitingObservational study
Lidocaine Infusions for Pain in Patients With Malignant Bowel Obstruction
Malignant Bowel Obstruction, Cancer Pain
Active, not recruitingObservational study
Patients Referred to the Chronic Pain Unit for Palliative Treatment With Ozone Therapy Between 2022 and 2025
Radiation Toxicity, Chemotherapeutic Toxicity
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Pain, Intractable and Pain, Chronic, run by Erasme University Hospital at 1 site in Belgium.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 25 Feb 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Patient satisfaction (time frame: 6 month). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Feb 2025; AzTrials last refreshed its copy on 7 Nov 2026.